{
    "clinical_study": {
        "@rank": "151192", 
        "acronym": "TBD", 
        "arm_group": [
            {
                "arm_group_label": "Main study population", 
                "description": "All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age.\nPatients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months."
            }, 
            {
                "arm_group_label": "Schizophrenia SoC sample", 
                "description": "Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic)."
            }, 
            {
                "arm_group_label": "Bipolar SoC sample", 
                "description": "Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant [N06A], antipsychotic (other than Quetiapine XR) [N05A] or mood stabilizer (including lithium [N05AN], valproate [N03AG01], and lamotrigine [N03AX09]."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to describe patient characteristics (demographic and clinical) and\n      the patterns of use of Quetiapine XR in patients receiving the drug for the first time in\n      real-life practice regardless the final diagnosis."
        }, 
        "brief_title": "Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Schizophrenia", 
            "Bipolar Episodes"
        ], 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "detailed_description": {
            "textblock": "Description of the use of Quetiapine Extended Release (XR) in real-life practice in France"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  New patients treated with Xeroquel XR\n\n          -  Patients aged 18 years and over\n\n          -  Diagnosis of bipolar disorder or schizophrenia according to DSM-IV criteria\n\n        Exclusion Criteria:\n\n          -  Patient included in a therapeutic trial (Huriet-Serusclat Act)\n\n          -  Patient refusing to participate in the study\n\n          -  Pregnant women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Hospital, clinic"
            }
        }, 
        "enrollment": {
            "#text": "1400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689389", 
            "org_study_id": "NIS-NFR-SER-2012/1"
        }, 
        "intervention_browse": {
            "mesh_term": "Quetiapine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Schizophrenia", 
            "Bipolar episodes", 
            "France", 
            "Xeroquel", 
            "Real-life"
        ], 
        "lastchanged_date": "February 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Argenteuil Cedex", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belley", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Castelmaurou", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cavaillon", 
                        "country": "France"
                    }, 
                    "name": "Reserach Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Les Mureaux", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nimes Cedex", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Obernai", 
                        "country": "France"
                    }, 
                    "name": "Research SIte"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saintes Cedex", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sens", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Dizier", 
                        "country": "France"
                    }, 
                    "name": "research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Egreve Cedex", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ussel Cedex", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "3", 
        "official_title": "Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France", 
        "overall_official": [
            {
                "affiliation": "Paris", 
                "last_name": "Bruno FALISSARD, Pr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Clermont-Ferrand", 
                "last_name": "Pierre-Michel LLORCA, Pr", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "France: French Data Protection Authority", 
                "France: Transparency Commission of the Haute Autorite de Sante (French National Authority for Health)", 
                "France: AFSSAPS-ANSM (French Health Products Safety Agency) Risk Management Plan"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Variables related with how the drug is prescribed and used by the patient [doses in mg/day, titration (yes/no), time of administration (morning/middle of the day/afternoon/evening), concomitant treatments] are going to be described.", 
                "measure": "Descriptive analysis of variables related with how the drug is prescribed and used by the patient.", 
                "safety_issue": "No", 
                "time_frame": "At inclusion"
            }, 
            {
                "description": "Age, gender, educational and professional status, co-habitation are going to be described.", 
                "measure": "Description of patient's socio-demographics profile.", 
                "safety_issue": "No", 
                "time_frame": "At inclusion"
            }, 
            {
                "description": "Diagnosis, family history of psychiatric disorders, number of suicidal attempts within the last 12 months, co-morbidities, treatments received during the last 12 months, laboratory and exam data will be included in the description.", 
                "measure": "Descriptive analysis of medical history.", 
                "safety_issue": "No", 
                "time_frame": "At inclusion"
            }, 
            {
                "description": "The Clinical Global Impressions Scale - Severity (CGI-S) assesses the clinician's impression of the current state of the patient's illness.\nThe following scores can be given: 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill patients.", 
                "measure": "Severity of the disease measured by Clinical Global Impressions Scale - Severity (CGI-S).", 
                "safety_issue": "No", 
                "time_frame": "At inclusion"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689389"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The Clinical Global Impressions Scale - Severity (CGI-S) assesses the clinician's impression of the current state of the patient's illness.\nThe following scores can be given: 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill patients.", 
                "measure": "Change in Clinical Global Impressions Scale - Severity (CGI-S) during the treatment.", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 months"
            }, 
            {
                "measure": "Quetiapine XR and concomitant treatment stop, stop date, reasons to stop, restart, restart date, reasons to restart.", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 months"
            }, 
            {
                "measure": "Descriptive analysis of the treatment changes: drug switches.", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 months"
            }, 
            {
                "measure": "Description of patterns of healthcare management resource use related with psychiatric disorders under investigation.", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 months"
            }, 
            {
                "measure": "Change in Body Mass Index (BMI).", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 months"
            }, 
            {
                "description": "Blood test- cholesterol.", 
                "measure": "Laboratory tests- cholesterol.", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 months"
            }, 
            {
                "measure": "Descriptive analysis of all adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to 12 months"
            }, 
            {
                "description": "New psychiatric hospitalisation, deterioration of the CGI-S (Clinical Global Impressions Scale - Severity) by at least 3 points for a baseline score of 1, at least 2 points for a baseline score of 2 or 3, at least 1 point for a baseline score of 4.", 
                "measure": "Relapses (only for the schizophrenia subpopulation).", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 months"
            }, 
            {
                "description": "Blood test- glycemia.", 
                "measure": "Laboratory tests- glycemia.", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 12 months"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}